Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement
Authors' conclusion
A substantial amount of literature was published on JAKi safety since 2019.
Study context
- Population
- Patients with immune-mediated inflammatory diseases (IMIDs) treated with Janus kinase inhibitors (JAKi): placebo- or active-controlled randomised controlled trials (RCTs), long-term extension (LTE) studies, pooled trial analyses, cohort and claims studies209 records included
- Outcome
- Safety outcomes of JAKi in IMIDs
Methodological detailsupdate of the 2019 systematic literature review (SLR), MEDLINE, Embase and Cochrane Library, Performed to inform the 2024 update of the expert consensus statement on treatment of IMIDs with JAKi
- Update of the 2019 SLR
- MEDLINE, Embase and Cochrane Library
- Performed to inform the 2024 update of the expert consensus statement on treatment of IMIDs with JAKi
Main finding
As reported in the abstract
Safety of JAKi
- Records screened
- 13,905
- Records included
- 209
- Safety trials
- 3
- Post hoc analyses
- 13
- Efficacy RCTs with adequate safety reporting
- 83
- Integrated safety analyses and LTE of RCTs
- 56
- Additional conference abstracts on RCT data
- 20
- Real-world cohort studies
- 37
Original publication
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement. Ann Rheum Dis. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →